Identifying the multiple dysregulated oncoproteins that contribute to tumorigenesis in a given patient is crucial for developing personalized treatment plans. However, accurate inference of aberrant protein activity in biological samples is still challenging as genetic alterations are only partially predictive and direct measurements of protein activity are generally not feasible. To address this problem we introduce and experimentally validate a new algorithm, virtual inference of protein activity by enriched regulon analysis (VIPER), for accurate assessment of protein activity from gene expression data. We used VIPER to evaluate the functional relevance of genetic alterations in regulatory proteins across all samples in The Cancer Genome Atlas (TCGA). In addition to accurately infer aberrant protein activity induced by established mutations, we also identified a fraction of tumors with aberrant activity of druggable oncoproteins despite a lack of mutations, and vice versa. In vitro assays confirmed that VIPER-inferred protein activity outperformed mutational analysis in predicting sensitivity to targeted inhibitors.
Cancer initiation and progression are driven by aberrant activity of oncoproteins working in concert to regulate critical tumor hallmark programs 1 . Pharmacological inhibition of aberrantly activated oncoproteins can elicit oncogene dependency 2 , which motivates the development and use of targeted inhibitors in precision cancer medicine. Activating genetic alterations have thus emerged as important candidate drug targets. Yet activating mutations represent only one of many possible ways to dysregulate the activity of an oncoprotein. Genetic and epigenetic events in cognate binding partners 3 , competitive endogenous RNAs 4 and upstream regulators 5 can all contribute to aberrant activity of oncoproteins. Thus, although cells with activating mutations in a specific oncogene are generally more sensitive to corresponding targeted inhibitors, cells lacking these mutations may also present equivalent sensitivity 6, 7 . Conversely, an activating mutation is not guaranteed to induce aberrant protein activity, due to autoregulatory mechanisms and epigenetic allele silencing. A more universal and systematic methodology for the accurate and reproducible assessment of protein activity would complement our ability to identify targeted therapy responders based on mutational analysis, especially because most cancer patients have no actionable oncogene mutations 8 .
While gene expression data are ubiquitous in cancer research [9] [10] [11] [12] , methods for the genome-wide assessment of protein activity are still elusive. Existing methods to measure protein abundance based on arrays 13 or mass spectrometry technologies 14 are still labor-intensive, costly, and either cover a small fraction of the proteomic landscape or require large amounts of tissue. More importantly, these methods provide only an indirect measure of protein activity, because the latter is determined by a complex cascade of events, including protein synthesis, degradation, post-translational modification, complex formation and subcellular localization 15 (Fig. 1a) . It is ultimately unclear whether protein activity may be directly and systematically assessed by any individual assay.
We propose that the expression of the transcriptional targets of a protein, collectively referred to as its regulon, represent an optimal multiplexed reporter of its activity (Fig. 1a) . Although this concept is not new and was initially proposed for transcription factors 16 , it has not been successfully demonstrated in mammalian cells. There are currently no experimentally validated methods to accurately assess the activity of arbitrary proteins in individual samples based on the expression of their regulon genes. Reasons for this include a lack of accurate and context-specific protein regulon models, the largely pleiotropic nature of transcriptional regulation, and a lack of methodologies to assess statistical significance from single samples. This severely limits the ability to understand the functional effect of mutations on protein activity and to identify candidate responders to targeted inhibitors based on aberrant protein activity rather than mutations.
We have previously shown that regulon analysis, using the master regulator inference algorithm (MARINa), can help identify aberrantly activated tumor drivers [17] [18] [19] [20] [21] . However, this requires multiple samples representing the same tumor phenotype and cannot be used to assess aberrant protein activity from individual samples. To address this challenge, we introduce a new regulatory-network based approach to infer protein activity from single gene expression profiles (VIPER; Supplementary Table 1 ). We first discuss development, optimization and validation of VIPER. Then we introduce a statistical framework to allow single-sample analysis, without loss of robustness or generality. Finally, we describe the use of VIPER to evaluate all non-silent somatic mutations in TCGA samples and report the aberrant activity of all oncogenes listed in the Catalogue Of Somatic Mutations In Cancer (COSMIC) 22 on an individual sample basis. VIPER can be used to systematically assess aberrant activity of oncoproteins for which high-affinity inhibitors are available, independent of their mutational state, thus establishing them as valuable therapeutic targets on an individual patient basis. The analysis is fully general and may be trivially extended to study the role of germ-line variants in dysregulating protein activity. We implemented VIPER as an R-system package available through Bioconductor.
RESULTS
The algorithm VIPER infers protein activity by systematically analyzing expression of the protein's regulon, which is strongly tumor-context-dependent 20 (Fig. 1b) . We used the algorithm for the reconstruction of accurate cellular networks (ARACNe 23 ; Online Methods) to systematically infer regulons from tissue-specific gene expression data ( Fig. 1b and Table 1 ). Although any algorithm or experimental assay providing accurate, tissue-specific assessments of protein regulons should be equally effective, we found that ARACNe outperformed competing algorithms that derive regulons from genome-wide chromatin immunoprecipitation (ChIP) databases, including ChIP enrichment analysis (ChEA) 24 and Encyclopedia of DNA Elements (ENCODE) 25 and literature curated Ingenuity networks 26 (see below). We extended ARACNe to detect maximum information path targets (Online Methods), as originally proposed in ref. 21 , to allow identification of regulons that report on the activity of proteins representing indirect regulators of transcriptional target expression, such as signaling proteins.
VIPER is based on a probabilistic framework that directly integrates target 'mode of regulation' , that is, whether targets are activated or repressed ( Fig. 1b and Supplementary Figs. 1 and 2) , statistical confidence in regulator-target interactions ( Fig. 1b) and target overlap between different regulators (pleiotropy) ( Fig. 1d) to compute the enrichment of a protein's regulon in differentially expressed genes (Online Methods). Several methods exist for gene enrichment analysis, including the Fisher's exact test 27 , T-profiler 28 and gene set enrichment analysis (GSEA) 27, [29] [30] [31] . In all these methods, the contribution of individual genes to signature enrichment is binary (i.e., 0 or 1). In contrast, VIPER uses a fully probabilistic yet efficient enrichment analysis framework, supporting seamless integration of genes with different likelihoods of representing activated, repressed or undetermined targets, and probabilistic weighting of low vs. high-likelihood protein targets. To achieve this, we introduce analytic rank-based enrichment analysis (aREA) a statistical analysis based on the mean of ranks ( Fig. 1c and Online Methods). Differential protein activity is quantitatively inferred as the normalized enrichment score computed by aREA.
Systematic assessment of VIPER's performance
We first tested VIPER's ability to correctly infer loss of protein activity following RNA interference (RNAi)-mediated silencing of a gene. a n a ly s i s npg a n a ly s i s silencing ( Table 2) . We included multiple cell lines and distinct RNAi silencing protocols and profiling platforms to avoid bias associated with these variables. We used these data to benchmark different regulatory model attributes and enrichment methods.
We assessed three metrics: (i) the P-value-based rank of the silenced gene (accuracy), (ii) the total number of statistically significant regulators inferred by VIPER (specificity), and (iii) the overall P value of the silenced gene. The enrichment analysis methods 18 and onetail GSEA. We also tested extensions of FET and GSEA to account for the mode of regulation of a target gene (two-tail FET and twotail GSEA), which were previously implemented in our MARINa algorithm 17, 18, 20 . Use of a three-tail aREA (aREA-3T), accounting for target mode of regulation, confidence and pleiotropic regulation, systematically outperformed all other approaches ( Fig. 1e,  Supplementary Figs. 3a and 4 , Supplementary Table 2 and Supplementary Note). Thus, we selected the aREA-3T method as the methodology of choice for the VIPER algorithm. The experimentally silenced proteins encoded by MYB, BCL6, STAT3, FOXM1, MEF2B and BCL6, were ranked as the 1 st , 1 st , 1 st , 2 nd , 3 rd and 3 rd most significantly inactivated proteins among all those tested, respectively ( Supplementary Fig. 3a and Supplementary Table 2 ). The small number of additional transcription factors inferred by aREA was enriched in differentially expressed genes and thus likely represents downstream targets of the silenced regulators or RNAi off-target effects (Supplementary Fig. 5 ).
To evaluate suitability of ARACNe-inferred regulons for use in VIPER, we benchmarked VIPER performance with non-contextspecific regulons, as assembled from ChIPsequencing (ChIP-seq) data in ChEA 24 and in ENCODE 25 . We also benchmarked VIPER against the upstream regulator module of Ingenuity Pathway Analysis 26 . ARACNebased VIPER outperformed these approaches ( Supplementary Fig. 3c and Supplementary Note). The alternative methods/models correctly assessed protein activity decrease only for FOXM1 following its silencing. Among the five tested transcription factors, FOXM1 was the only one representing a core cell cycle regulator, whose regulon is strongly conserved across multiple tissue contexts ( Supplementary Fig. 3d ), thus not requiring use of context-specific regulatory models.
From each experiment we generated signatures using the controlsample-based Z transformation (Online Methods) to allow analysis of individual samples ( Table 2) . Results from single-sample analyses were virtually identical to those obtained with the multisample version of VIPER ( Fig. 1e, Supplementary Fig. 3b and Supplementary Table 3 ), suggesting that single-sample analysis produces robust and highly reproducible results. We then performed several additional benchmarks to assess the specific improvements owing to the aREA probabilistic analysis, compared to GSEA, and to assess the overall ability of the algorithm to correctly identify proteins whose activity was modulated by RNAi and small-molecule perturbations, or whose abundance was quantified by reverse-phase protein arrays (Supplementary Figs. 6-9, npg a n a ly s i s Supplementary Tables 4-6 and Supplementary Note). Based on our benchmarking results, we generated a comprehensive map of protein activity dysregulation in response to short-term pharmacologic perturbations. We selected 166 compounds in CMAP 33 that induced reproducible perturbation profiles across replicates (FDR < 0.05, Supplementary Note) and report their effect on the activity of 2,956 regulatory proteins in Supplementary Table 7 .
Algorithm robustness
Poor reproducibility across biological replicates is a critical reason why gene expression analysis has not been broadly adopted in clinical tests. We thus rigorously assessed the reproducibility of the VIPER inferences as a result of multiple sources of technical and biological noise ( Fig. 2) . Regulons were degraded by progressively randomizing regulatory interactions while maintaining network topology. Although VIPER's performance depends on availability of tissue-specific regulons ( Fig. 2a) , it tolerates a high fraction of false positive interactions, with noticeable performance degradation observed only when >60% of regulon interactions were randomized ( Fig. 2b) . Assuming ~30% false positive rate by ARACNe 34, 35 , this suggests that as long as >28% of genes in a regulon represent bona fide regulatory interactions, protein differential activity can be accurately inferred.
VIPER assessment of protein activity was robust to reduced regulon representation, as confirmed by the analysis of the library of integrated network-based cellular signatures (LINCS) data ( Supplementary Fig. 7 and Supplementary Note). Progressive target removal starting with those with lowest mutual information further increased accuracy, with optimal accuracy achieved at n = 50 targets and only modest degradation down to n = 25 targets ( Fig. 2c) . Regulons of fewer than 25 targets showed a dramatic decrease in accuracy ( Fig. 2c) .
VIPER was also highly insensitive to gene expression signature degradation, as seen by adding zero-centered Gaussian noise with increasing variance (comparable to benchmark data sets variance) ( Fig. 2d) . This makes it well-suited for assessment of protein activity from noisy single-sample gene expression profiles, where the variance of VIPER-inferred activity is much smaller than the variance of gene expression ( Fig. 3a,b and Supplementary Fig. 10 ). For instance, considering a B cell phenotype, VIPER-based protein activity signatures were significantly more correlated than gene expression signatures (P < 10 −15 , Wilcoxon signed-rank test; Fig. 3a and Supplementary  Fig. 10a ). Addition of Gaussian noise decreased expression-based sample-sample correlation with only a minimal effect on VIPERinferred activity correlation (Supplementary Fig. 10b ). VIPER activity was highly resilient to reduced transcriptome representation, showing minimal accuracy decrease when up to 90% of the genes in the signature were removed from the analysis ( Fig. 2e) or when RNA-seq profiles where subsampled from 30 million (M) reads to 0.5 M reads (Fig. 2f) , making VIPER appropriate for the analysis of low-depth RNA-seq profiles. This was further evidenced when comparing protein activity profiles inferred from fresh-frozen vs. matched formalin-fixed paraffin-embedded (FFPE) samples ( Fig. 3c and Supplementary Fig. 10c) . The reproducibility of the results from FFPE samples represents a critical prerequisite for precision medicine applications.
To assess the effect of biological variability, we computed VIPER activity signatures for 173 TCGA basal breast carcinomas. VIPERinferred activity signatures were significantly more correlated across samples (P < 10 −15 by Wilcoxon signed-rank test for the correlation coefficients, Supplementary Fig. 10d ) and top-ranking aberrantly activated proteins were more conserved across samples based on differential activity than on differential expression of the associated gene (Fig. 3b) . Overall sample-to-sample variance was reduced more than 250-fold compared to gene expression ( Fig. 3b) . Thus, VIPERinferred differentially activated proteins are much more conserved than differentially expressed genes or differentially abundant proteins (based on RPPA measurements) across different samples representing the same tumor subtype ( Fig. 3b) .
Functionalizing the somatic mutational landscape of cancer
Based on these benchmarks, we used VIPER to systematically test the effect of recurrent mutations on corresponding protein activity. We considered a pan-cancer set of 3,912 TCGA samples, representing 14 tumor types, for which exome data are available ( Supplementary  Table 8 ). We first computed the VIPER-inferred activity of each transcription factor and signaling protein in each of the analyzed samples and tested whether samples harboring recurrent mutations were enriched in those with high VIPER-inferred differential activity of the affected protein. From 150 recurrently mutated genes in COSMIC, we selected 89 that were mutated in at least 10 samples in at least one tumor type and for which a matching regulatory model was available (Supplementary Table 8 ). This identified a total of 342 pairs (for example, EGFR in glioblastoma multiforme, GBM) where a specific oncoprotein could be tested in a specific tumor cohort. npg a n a ly s i s
As protein activity may depend on either total protein abundance or on the abundance of specific, differentially active isoforms, we estimated both global VIPER activity and the residual post-translational (RPT) VIPER activity (the component of activity that cannot be accounted for by differential expression) by removing the transcriptional variance component (Online Methods). By definition, RPT activity is statistically independent of gene expression and should account for the purely post-translational contribution to protein activity. Almost 30% of subtype-specific variation-harboring proteins (92/342) were associated with statistically significant differential protein activity, as assessed by VIPER (P < 0.05): 65/342 (19%) by global activity analysis and 51/342 (15%) by RPT activity analysis, respectively (Supplementary Fig. 11 ). This included the vast majority of established oncogenes and tumor suppressors ( Fig. 4 and Supplementary Fig. 11a,b ), suggesting that this integrative analysis provides an effective means to capture mutation-dependent dysregulation of oncogene and tumor suppressor activity ( Supplementary  Fig. 11 ). VIPER-inferred RPT activity effectively eliminates the effect of feedback loops on the corresponding gene's expression, thus identifying mutations resulting only in post-translational effects (Supplementary Fig. 11a,b) . We observed that 45% of mutations associated with VIPER-inferred differential activity (41/92) induced no significant differential expression of the corresponding gene ( Fig. 4a  and Supplementary Fig. 11a ), including mutations in established oncogenes and tumor suppressors, such as TP53, PTEN, NFE2L2, ARID1A, CARD11, BRCA2, CTNNB1, MLH1, VHL and SMAD4, among others ( Fig. 4a and Supplementary Fig. 11a) .
To assess whether a pharmacologically targetable protein may be aberrantly activated in a tumor sample, independent of the sample's mutational state, we define a sample's mutant phenotype score (MPS). This represents the probability of observing mutations in samples with equal or higher total VIPER activity ( Supplementary Fig. 12 ). This is computed as the fraction of mutated vs. wild-type (WT) samples for the specific protein and tumor type. We thus ranked samples based on their MPS for each of the 92 protein/tumor-type pairs for which mutated samples were enriched in differentially activated proteins based on our previous analysis (Online Methods). Although the majority of mutated samples had a high MPS, a few had a low MPS, comparable to WT samples, suggesting nonfunctional mutations, or subclonal mutations or regulatory compensation of their effect ( Fig. 5a  and Supplementary Fig. 12) , including samples harboring activating mutations in actionable proteins, such as those encoded by EGFR, ERBB2, BRAF and PI3K, with MPSs ≤ −0.5 (i.e., threefold more likely to have WT activity) ( Fig. 5a ), suggesting subpar response to targeted inhibitors. Many WT samples had MPSs ≥ 0.5 (i.e., threefold more likely to have mutated activity) ( Fig. 5a ), suggesting they may respond to targeted inhibitors.
Validating drug sensitivity
To assess whether the MPS is a good predictor of drug sensitivity, we performed EGFR-specific MPS analysis of 79 lung adenocarcinoma cell lines, for which gene expression profiles, EGFR status and chemosensitivity to EGFR inhibitors were available from the Cancer Cell Line The complete list of evaluated proteins is available in supplementary Figure 11 . For each indicated gene harboring nonsilent somatic mutations, the proportion of mutated samples from that tumor type is indicated. Violin plots indicate the distribution density for the mutated samples on all samples rank-sorted by mRNA expression (yellow) and VIPER-inferred protein activity (cyan); background color gradient indicates both expression and VIPER-inferred protein activity signatures: downregulated genes and inactivated proteins (blue) and overexpressed genes and activated proteins (red). Bar plots show significance for the association computed by the aREA algorithm. Blue and red bars indicate enrichment of the mutated samples among low expression or protein activity, and among high levels of expression or protein activity, respectively. a n a ly s i s Encyclopedia 7 , including saracatinib (AZD0530), erlotinib and lapatinib. Of the cell lines with low EGFR MPS (< −0.5) that yet harbored EGFR mutations, 0/2, 1/2 and 1/2 were sensitive to AZD0530, erlotinib and lapatinib, respectively. Conversely, 5/6, 5/6 and 4/6 of those with MPS > 0.5, were sensitive to those drugs, respectively ( Fig. 5b) , suggesting a strong association between MPS and chemosensitivity in EGFR-mutated cell lines. Moreover, considering only EGFR WT cell lines, the fraction responding to EGFR inhibitors was higher among those with MPS > 0.5 (50% vs. 33% for AZD0530, 43% vs. 33% for erlotinib and 36% vs. 27% for lapatinib, respectively) compared to those with MPS < −0.5 (Fig. 5b) . MPS was significantly associated with chemosensitivity, regardless of EGFR mutation status, by Pearson correlation analysis (P < 10 −5 for each of the three drugs; Fig. 5b) , and by comparing sensitivity of cells with MPS > 0.5 and MPS < −0.5 by Student's t-test (P < 0.01 and P < 0.05 for AZD0530 and erlotinib, respectively Fig. 5b ).
Assessing the role of site-specific mutations
In the previous analysis, all mutations in a gene were considered equivalent. We next tested whether VIPER could also be used to assess differential activity associated with mutations at specific protein sites. This could be instrumental in elucidating the functional effect of rare or private mutations. Specifically, we tested whether different mutations in the same gene (for example, p.Gly12Val vs. p.Gly12Asp changes for the KRAS product) may produce quantitatively distinct effects on protein activity. We assessed all mutations affecting COSMIC genes that were detected in at least two samples of the same tumor type, based on four quantitative measurements: (i) their VIPER-inferred global activity, (ii) their VIPER-inferred RPT activity, (iii) their differential gene expression, and (iv) their MPS (for mutations affecting at least 10 samples). In total, we analyzed 648 locus-specific mutations in 49 distinct genes, across 12 tumor types ( Supplementary Fig. 13) .
In Figure 6 we summarized the cases with adequate statistical power. Careful examination showed that functional impact of these mutations was both variant-specific (for example, KRAS: p.Gly12Val vs. p.Gly12Asp in colon adenocarcinoma (COAD); Fig. 6a ) and tumor specific (for example, KRAS: p.Gly12Ala in COAD vs. lung adenocarcinoma (LUAD); Fig. 6a ). In addition, although some mutations induce effects equivalent to differential expression, others produce exquisitely post-translational effects that can only be predicted by RTP activity (for example, KRAS: p.Gly12Val in LUAD vs. p.Gly13Asp in COAD; Fig. 6a and Supplementary Fig. 13 ).
Although different mutations may have similar impact on protein activity (for example, all TP53 functional variants were associated with reduction in inferred TP53 protein activity), their effects on gene expression were highly heterogeneous. For instance, nonsense and frame-shift mutations in TP53 invariably reduced mRNA levels (Fig. 6a) , likely due to nonsense and nonstop-mediated mRNA decay 36 . In contrast, missense mutations were consistently associated with increased mRNA levels, likely due to feedback loops attempting to compensate for mutation-induced loss of TP53 protein activity (Fig. 6a) 37 . Such dichotomy in TP53 somatic variant effect may explain the lack of association between mutations and gene expression, when all variants are considered together (Fig. 4a) .
To compensate for the lack of statistical power due to the potentially small number of samples harboring locus-specific mutations (Supplementary Fig. 13) , we performed integrated analysis across all tumor types. We accounted for heterogeneity among tumor types by aggregating the samples at the protein activity level, originally inferred using tissue-matched interactomes. This yielded a pan-cancer repertoire of functionally relevant somatic variants, based on the analysis of 3,343 samples across 12 tumor types, for which we npg a n a ly s i s report the statistical association between each locus-specific mutation and its MPS, as well as the pan-cancer VIPER P value ( Fig. 6b and  Supplementary Fig. 14) .
DISCUSSION
Precision cancer medicine currently relies on the identification of actionable mutations. These can be reproducibly identified from whole-genome and exome analysis of tumor tissue and have demonstrated clinical relevance. However, only ~25% of adult cancer patients present with potentially actionable mutations 8 . Thus, methodologies, such as VIPER, for inferring aberrant protein activity, independent of mutational state, may complement and greatly extend available genomic approaches. Indeed, genetic mutations are neither necessary nor sufficient to induce aberrant activity and tumor essentiality of protein isoforms. An increasing catalog of non-oncogene dependencies has emerged in recent years 5, 18, 20, 21, 38, 39 , whose aberrant activity depends on indirect genetic alterations, such as those in upstream pathways and cognate binding proteins. It is not surprising that many tumor cells respond to inhibitors targeting established oncoproteins, such as EGFR, even in the absence of activating mutations, as shown by large-scale dose-response studies in the cancer cell line encyclopedia 6, 7 and by recent analysis of pathways upstream of functional tumor drivers 5 . VIPER has three critical roles. First, it helps elucidate aberrant protein activity resulting either from direct or pathway-mediated mutations. Second, it can help prioritize the functional relevance of rare and private nonsynonymous mutations as hypomorph, hypermorph or neutral events. Systematic analysis of TCGA cohorts showed that 27% of nonsynonymous mutations induced aberrant VIPER-inferred protein activity. This is a substantial fraction, especially considering that not all mutations substantially affect protein activity on canonical targets, including those resulting in entirely new protein functions (neopmorphs), and that mutation clonality was not accounted for in these studies. Third, VIPER can help distinguish between transcriptionally and post-translationally mediated mutational effects (Figs. 4a-c and 6) .
Systematic VIPER of TCGA samples (Fig. 5a) showed that although genetic alterations strongly co-segregated with aberrant VIPER-inferred oncoprotein activity, many WT samples had VIPERinferred activity comparable to and even greater than those harboring actionable mutations. This is critically relevant for alterations in pharmacologically actionable oncogenes, such as BRAF, EGFR, ERBB2 and FGFR3, among others, suggesting that VIPER may be used to identify additional patients who may benefit from targeted therapy. Similarly, VIPER identified samples with actionable mutations presenting no aberrant activity of the corresponding oncoprotein. Validation of the predictive value of VIPER-inferred activity to infer targeted inhibitor response, using the cancer cell line encyclopedia, suggests that the algorithm may provide valuable insight in precision cancer medicine.
Several approaches have been proposed to estimate pathway activity 40, 41 , co-regulation of gene expression modules 42 or activity of selected proteins 43 from gene expression signatures. These, however, do not predict activity of arbitrary proteins, lack tumor specificity and cannot be used to analyze individual samples. Other approaches developed for yeast 44 and other model organisms [44] [45] [46] [47] have never been extended to mammalian cells. Earlier attempts based on transcription factor targets inferred from promoter sequence analysis 16 or from proprietary, literature-based networks 26 have not been systematically validated. As a result, with the exception of VIPER, to our knowledge there are currently no validated methods to systematically predict the activity of all signal transduction and transcription factors proteins in individual samples.
VIPER leverages protein regulons reverse-engineered from primary tumor sample data to quantitatively assess differential protein activity in individual samples, without any manual annotation or curated gene sets. Critically, VIPER's performance is extremely robust and resilient to signature noise, regulon subsampling and sample quality. Indeed, VIPER accurately inferred protein activity for ~50% of all regulatory proteins using <1,000 genes from LINCS perturbational signatures (Supplementary Fig. 7) . Furthermore, inference of differentially active proteins from fresh-frozen or FFPE samples from the same tissue was highly correlated, even though correlation of the corresponding gene expression data was low. VIPER predictions were remarkably reproducible across samples belonging to the same molecular tumor subtype. This is critically important for precision medicine applications.
Tissue specificity of protein-target is a critical element of our analysis. Genes with expression affected by changes in protein activity are highly context-specific 35 , owing to lineage-specific chromatin remodeling, combinatorial regulation by multiple transcription factors and post-translational modification. This is supported by the fact that inference of protein activity using the incorrect regulatory model produced substantially degraded results ( Fig. 2a) .
VIPER constitutes only a partial contribution toward the ultimate goal of accurately measuring protein activity in mammalian samples. Yet our data suggest that improvements in the accuracy and coverage of regulatory models could further increase the quality and breadth of these predictions, thus helping determine which proteins drive key pathophysiological phenotypes. We illustrated the potential application of VIPER to mine existing data sets, including expression profiles in TCGA and LINCS. Finally, VIPER has the power to infer relative protein activity as an extra layer of information, providing additional evidence over classical genetics and functional genomics data to assess the effect of nonsilent mutations.
URLs. VIPER package for the R system is available from Bioconductor at http://www.bioconductor.org/packages/release/bioc/html/viper.html. VIPER package vignette, http://bioconductor.org/packages/release/bioc/ vignettes/viper/inst/doc/viper.pdf; The Cancer Genome Atlas, http:// cancergenome.nih.gov/; ChEA database, http://amp.pharm.mssm.edu/ Enrichr/#stats; CMAP, https://www.broadinstitute.org/cmap/.
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